U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07636226) titled 'QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer' on June 04.
Brief Summary: This is a multicenter, open-label, randomized controlled phase II/III study evaluating the efficacy and safety of QL1706 in combination with anlotinib as later-line treatment in patients with advanced lung cancer.
Study Start Date: July 30
Study Type: INTERVENTIONAL
Condition:
Small Cell Lung Cancer
Intervention:
DRUG: QL1706
Every 3 weeks, 5mg/kg of QL1706 is administered intravenously until the disease progresses.
DRUG: Anlotinib
10mg Anlotinib is administered orally. It is given daily for the first 14 days, ...